Skip to content

Clinical trials

Active, not recruiting Leukemia, Myelogenous, Chronic, BCR-ABL Positive trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Leukemia, Myelogenous, Chronic, BCR-ABL Positive Status: Active, not recruiting Country / region: United States Clear all

26 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20041
20081
20111
20141
20163
20171
20195
20202
20213
20224
20232
20241
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Active, not recruiting26

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Baylor College of Medicine4
M.D. Anderson Cancer Center3
Center for International Blood and Marrow Transplant Research2
Novartis Pharmaceuticals2
St. Jude Children's Research Hospital2
Children's Oncology Group1
Dana-Farber Cancer Institute1
Fred Hutchinson Cancer Center1
H. Lee Moffitt Cancer Center and Research Institute1
MacroGenics1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Leukemia, Myelogenous, Chronic, BCR-ABL Positive26
Precursor Cell Lymphoblastic Leukemia-Lymphoma15
Myelodysplastic Syndromes14
Leukemia, Myeloid, Acute13
Lymphoma, Non-Hodgkin9
Hodgkin Disease6
Lymphoproliferative Disorders5
Myeloproliferative Disorders5
Leukemia4
Leukemia, B-Cell4

Trials

Showing 1 to 25 of 26. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.